Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Federal psychedelic therapy policy shifts from prohibition to expedited research

Federal psychedelic therapy policy shifts from prohibition to expedited research

Rule Changes
By Newzino Staff |

Executive order directs FDA to fast-track psychedelic clinical trials, opens Right to Try pathway for veterans with PTSD

Today: Trump signs executive order expediting psychedelic research

Overview

For 55 years, the federal government classified psilocybin, MDMA, LSD, and ibogaine as Schedule I substances — drugs with no accepted medical use. On April 18, 2026, President Trump signed an executive order directing the Food and Drug Administration (FDA) to issue new guidance expediting clinical trials of those same substances for treating post-traumatic stress disorder (PTSD) in veterans, made $50 million in federal funding available for state-level ibogaine research, and opened a pathway for seriously ill patients to access psychedelics under the Right to Try law.

Why it matters

Millions of veterans with treatment-resistant PTSD may gain access to therapies that have been federally prohibited for over five decades.

Key Indicators

$50M
Federal funding for ibogaine research
New federal dollars directed to state-level ibogaine research programs under the executive order.
4
Psychedelic substances covered
Psilocybin, MDMA, ibogaine, and LSD are named in the executive order for expedited FDA review.
55 years
Duration of Schedule I classification
These substances have been classified as having no accepted medical use since the Controlled Substances Act of 1970.
~13%
Estimated PTSD rate among US veterans
Roughly one in eight US veterans experiences PTSD, with many cases resistant to existing treatments.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Sign Up

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

Donald Trump
Donald Trump
Signed executive order on April 18, 2026
 Rick Perry
Rick Perry
Key advocate for ibogaine research for veterans
 Rick Doblin
Rick Doblin
Continuing advocacy after FDA's 2024 MDMA rejection
 J.D. Vance
J.D. Vance
Supporter of psychedelic therapy for veterans

Organizations Involved

U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal Agency
Directed by executive order to issue new guidance expediting psychedelic trials

The FDA controls the drug approval pipeline and has granted breakthrough therapy designations to several psychedelics, but rejected MDMA therapy in August 2024.
MAPS / Lykos Therapeutics
MAPS / Lykos Therapeutics
Nonprofit Research Organization / Pharmaceutical Company
Pursuing revised MDMA therapy application after 2024 FDA rejection

MAPS spent nearly four decades and over $100 million developing MDMA-assisted therapy for PTSD through the FDA approval process.
Heroic Hearts Project
Heroic Hearts Project
Veteran Advocacy Nonprofit
Active advocate for veteran access to psychedelic therapy

Connects military veterans suffering from PTSD with psychedelic therapy programs, often facilitating treatment abroad where the substances are legal.

Timeline

  1. Trump signs executive order expediting psychedelic research

    Executive Action

    President Trump signed an executive order directing the FDA to issue new guidance expediting clinical trials of psilocybin, MDMA, ibogaine, and LSD for veteran PTSD, making $50 million available for state-level ibogaine research and opening a Right to Try pathway for seriously ill patients.

  2. FDA rejects MDMA-assisted therapy for PTSD

    Regulatory

    The FDA formally rejected Lykos Therapeutics' application for MDMA-assisted therapy, following the advisory committee's recommendation. The rejection galvanized veteran advocacy groups and bipartisan congressional support for alternative pathways.

  3. FDA advisory committee votes against MDMA therapy approval

    Regulatory

    An FDA advisory committee voted against recommending approval of MDMA-assisted therapy for PTSD, citing concerns about clinical trial methodology, inadequate blinding, and potential risks of abuse.

  4. Colorado voters approve psychedelic access program

    Legislation

    Colorado passed Proposition 122, decriminalizing certain natural psychedelics and directing the state to create a regulated access program for psilocybin therapy.

  5. Oregon voters approve regulated psilocybin therapy

    Legislation

    Oregon passed Measure 109, creating the first state-regulated psilocybin therapy program in the United States. Licensed service centers began operating in 2023.

  6. FDA grants psilocybin breakthrough therapy designation

    Regulatory

    The FDA granted breakthrough therapy designation to psilocybin for treatment-resistant depression, developed by Compass Pathways. A second designation followed in 2019 for major depressive disorder via the Usona Institute.

  7. Trump signs Right to Try Act

    Legislation

    President Trump signed the Right to Try Act, allowing terminally ill patients to access investigational drugs that have completed Phase 1 trials without full FDA approval. The law's application to psychedelics was not envisioned at the time.

  8. FDA grants MDMA breakthrough therapy designation for PTSD

    Regulatory

    The FDA designated MDMA-assisted therapy as a breakthrough therapy for PTSD, signaling that preliminary clinical evidence showed it may offer substantial improvement over existing treatments and expediting its development.

  9. Rick Doblin founds MAPS to pursue legal psychedelic medicine

    Organization

    Doblin founded the Multidisciplinary Association for Psychedelic Studies with the explicit long-term goal of making MDMA a legal prescription medicine through the FDA approval process.

  10. MDMA added to Schedule I on emergency basis

    Regulation

    The Drug Enforcement Administration (DEA) placed MDMA into Schedule I using emergency scheduling authority, despite objections from researchers and a DEA administrative law judge who recommended Schedule III.

  11. Controlled Substances Act classifies psychedelics as Schedule I

    Legislation

    President Nixon signed the Controlled Substances Act, placing psilocybin, LSD, and other psychedelics into Schedule I — the most restrictive category, reserved for drugs deemed to have no accepted medical use and high abuse potential. This effectively halted decades of psychiatric research.

Scenarios

1

FDA approves first psychedelic therapy, rescheduling follows

Discussed by: Psychedelic medicine researchers, drug policy analysts, and industry advocates

Expedited FDA guidance leads to faster, better-designed clinical trials. One or more psychedelic substances — most likely psilocybin for depression or MDMA for PTSD — win FDA approval within 2-4 years. The executive order's rescheduling directive then moves the approved substance from Schedule I to a lower schedule, creating a legal framework for prescription use. This would represent the first federally approved psychedelic medicine since the 1970 Controlled Substances Act.

2

Right to Try becomes primary access channel, bypassing full approval

Discussed by: Veteran advocacy groups, libertarian-leaning policy analysts, and some Republican lawmakers

Rather than waiting years for full FDA approval, veterans and seriously ill patients begin accessing psychedelics through the Right to Try pathway. State-level ibogaine programs, funded by the $50 million allocation, create a patchwork of legal access. This de facto normalizes psychedelic therapy before the FDA formally approves any substance, creating political momentum that makes full prohibition untenable. Critics warn that safety monitoring in this scenario would be minimal compared to the clinical trial process.

3

FDA independence concerns stall implementation

Discussed by: Medical establishment figures, FDA staff, and some Democratic lawmakers

The FDA pushes back on executive pressure to expedite reviews, arguing that the MDMA rejection demonstrated real methodological problems that cannot be waved away by executive order. Legal challenges may arise over whether the Right to Try Act can be applied to Schedule I substances without DEA rescheduling. Implementation stalls in bureaucratic and legal disputes, with the executive order's practical impact limited to the $50 million ibogaine research allocation.

4

Safety incident triggers political reversal

Discussed by: FDA safety officials, addiction medicine specialists, and some psychiatrists

Expanded access through Right to Try or state programs leads to a serious adverse event — ibogaine carries known cardiac risks, and MDMA has abuse potential. A high-profile death or injury generates political backlash, particularly if it involves a veteran. The incident is used to justify tightening restrictions, potentially setting back the broader psychedelic therapy movement by years. This scenario echoes how individual incidents in the 1960s contributed to the blanket prohibition that followed.

Historical Context

Nixon's Controlled Substances Act ends first wave of psychedelic research (1970)

October 1970

What Happened

Between the 1950s and late 1960s, researchers conducted over 1,000 clinical studies on LSD and other psychedelics, treating an estimated 40,000 patients for conditions including alcoholism, depression, and end-of-life anxiety. The Controlled Substances Act placed these substances into Schedule I, effectively criminalizing all research and therapeutic use. The decision was driven more by the association of psychedelics with the counterculture movement than by clinical safety data.

Outcome

Short Term

Virtually all psychedelic research stopped. Scientists who had spent careers studying these compounds abandoned the field or moved abroad.

Long Term

A 40-year gap in psychedelic research. When trials resumed in the 2000s, researchers had to rebuild methodology and institutional knowledge from scratch.

Why It's Relevant Today

The current executive order represents the most significant federal reversal of the 1970 prohibition framework. Understanding that the original scheduling was politically rather than scientifically driven helps explain why breakthrough therapy designations and clinical evidence have not been sufficient to change policy through normal regulatory channels.

FDA rejection of MDMA therapy despite breakthrough designation (2024)

June–August 2024

What Happened

After 38 years and over $100 million in research, MAPS' pharmaceutical arm Lykos Therapeutics submitted an application for MDMA-assisted therapy for PTSD based on two Phase 3 trials showing significant symptom reduction. An FDA advisory committee voted 9-2 against recommending approval, citing concerns about study blinding (participants could often tell whether they received MDMA), therapist influence on outcomes, and inadequate safety data on abuse potential. The FDA followed the committee's recommendation and rejected the application in August 2024.

Outcome

Short Term

Lykos Therapeutics faced financial uncertainty. Veteran advocates who had expected approval felt betrayed by the regulatory process.

Long Term

The rejection shifted advocacy strategy from working within the FDA system to seeking political and executive intervention, directly contributing to the conditions that produced the April 2026 executive order.

Why It's Relevant Today

The MDMA rejection is the proximate cause of the executive order. It demonstrated that even with breakthrough therapy designation and positive clinical trial results, the standard FDA pathway could not deliver timely access — creating the political demand for an alternative approach.

Right to Try Act expands experimental drug access (2018)

May 2018

What Happened

President Trump signed the Right to Try Act, allowing patients with life-threatening conditions to request access to investigational drugs that had completed Phase 1 trials but not yet received full FDA approval. The law was championed by libertarian-leaning groups and the Goldwater Institute, and passed the Senate unanimously. In practice, relatively few patients used the pathway — most pharmaceutical companies preferred the existing FDA expanded access program.

Outcome

Short Term

Limited practical impact. Most drug companies continued routing compassionate use requests through the FDA's existing expanded access program.

Long Term

Established a legal precedent for patients to access unapproved drugs outside the FDA framework, which the 2026 executive order now extends to psychedelic substances.

Why It's Relevant Today

The executive order's extension of Right to Try to psychedelics tests the law's boundaries significantly. The original act was designed for terminally ill patients seeking experimental cancer drugs — applying it to Schedule I substances for PTSD represents a novel and potentially contested interpretation.

Sources

(4)
Bloomberg Fox News CBS News Marijuana Moment